The lncRNA UCA1 Enhances Pancreatic Cancer EMT by  Regulating miR-708-5p and miR-135b-5p: A Bioinformatics Approach

Nahid Askari; Marziye Shad Pirouz; Vida Mafikandi; Morteza Hadizadeh; Seyedeh Zahra Mousavi

The lncRNA UCA1 Enhances Pancreatic Cancer EMT by Regulating miR-708-5p and miR-135b-5p: A Bioinformatics Approach

Seyedeh Zahra Mousavi

Abstract

Background: Pancreatic cancer (PC) is an exceedingly malignant ailment that is not only characterized by its insidious onset and rapid progression but also by its poor therapeutic effects. Recently, emerging evidence has shed light on the significant role that non-coding RNAs (ncRNAs), particularly long ncRNAs (lncRNAs) and microRNAs (miRNAs), play in the pathogenesis of PC. This investigation aimed to construct a network of interactions between miRNAs, lncRNAs, and mRNAs, as well as to perform correlation analyses in the context of PC.

Methods: This study carried out in Kerman City, southeastern Iran in 2023. We utilized the GSE119794 dataset from the Gene Expression Omnibus (GEO) to analyze differentially expressed lncRNAs (DE-lncRNAs), miRNAs (DE-miRNAs), and mRNAs (DE-mRNAs). Following the identification of the DE-lncRNAs, DE-mRNAs, and DE-miRNAs, we proceeded to examine differentially expressed epithelial-mesenchymal transition (EMT) genes. Subsequently, we utilized the RNAInter database to predict interactions among lncRNAs, miRNAs, and mRNAs. Finally, we employed Cytoscape to visualize and analyze the constructed network.

Results: 14 DE-lncRNAs, 14 DE-miRNAs, 545 DE-mRNAs, and 65 DE-EMT from pancreatic cancer and its adjacent tissue RNA-Seq data were identified. 1184 EMT genes from dbEMT were obtained, among which 65 DE-EMT were assigned as EMT genes and correlated with tumor progression. One functional lncRNA (UCA1) was identified as a key functional lncRNA. The area under the ROC curve (AUC) of UCA1 and miR-708-5p were 0.79 and 0.86, respectively. Thus, it is reasonable to believe that this prognostic risk model helps predict PC metastasis.

Conclusion: UCA1 is a new lncRNA linked with EMT in PC and contributes to a better knowledge of the regulatory mechanisms related to lncRNAs in PC.

1. Klatte DC, Wallace MB, Löhr M, et al (2022). Hereditary pancreatic cancer. Best Pract Res Clin Gastroenterol, 58-59:101783.
2. Klein AP (2021). Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol, 18 (7):493-502.
3. Mizrahi JD, Surana R, Valle JW, Shroff RT (2020). Pancreatic cancer. Lancet, 395 (10242):2008-2020.
4. Ilic M, Ilic I (2016). Epidemiology of pancreatic cancer. World J Gastroenterol, 22 (44):9694-9705.
5. Shin EJ, Canto MI (2012). Pancreatic cancer screening. Gastroenterol Clin North Am, 41 (1):143-157.
6. Mario C, Marilisa F, Kryssia IR-C, et al (2018). Epidemiology and risk factors of pancreatic cancer. Acta Biomed, 89 (9-S):141-146.
7. Fedele M, Sgarra R, Battista S, et al (2022). The epithelial–mesenchymal transition at the crossroads between metabolism and tumor progression. Int J Mol Sci, 23 (2):800.
8. Gulla A, Andriusaityte U, Zdanys GT, et al (2022). The impact of epithelial–mesenchymal transition and metformin on pancreatic cancer chemoresistance: a pathway towards individualized therapy. Medicina (Kaunas), 58 (4):467.
9. Aiello NM, Brabletz T, Kang Y, et al (2017). Upholding a role for EMT in pancreatic cancer metastasis. Nature, 547 (7661):E7-E8.
10. Cao M-x, Jiang Y-p, Tang Y-l, Liang X-h (2017). The crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticity. Oncotarget, 8 (7):12472-12483.
11. Huang J, Liu J, Chen-Xiao K, et al (2016). Advance in microRNA as a potential biomarker for early detection of pancreatic cancer. Biomark Res, 4:20.
12. Yin J, Zeng X, Ai Z, et al (2020). Construction and analysis of a lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveal functional lncRNAs in oral cancer. BMC Med Genomics, 13:84.
13. Huang X, Zhi X, Gao Y, et al (2016). LncRNAs in pancreatic cancer. Oncotarget, 7 (35):57379- 57390.
14. Nukala SB, Jousma J, Cho Y, et al (2022). Long non-coding RNAs and microRNAs as crucial regulators in cardio-oncology. Cell Biosci, 12 (1): 24.
15. Naderi E, Mostafaei M, Pourshams A, Mohamadkhani A (2014). Network of microRNAs-mRNAs interactions in pancreatic cancer. Biomed Res Int, 2014: 534821.
16. Lv F, Zheng K, Yu J, Huang Z (2018). MicroRNA‑661 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation. Oncol Lett, 16 (5):6293-6298.
17. Bracken CP, Goodall GJ (2022). The many regulators of epithelial− mesenchymal transition. Nat Rev Mol Cell Biol, 23 (2):89-90.
18. Ashrafizadeh M, Rabiee N, Kumar AP, et al (2022). Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. Drug Discov Today, 27 (8):2181-2198.
19. Hong M, Tao S, Zhang L, et al (2020). RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol, 13 (1):166.
20. Lin J, Wu YJ, Liang X, et al (2019). Network‐based integration of mRNA and miRNA profiles reveals new target genes involved in pancreatic cancer. Mol Carcinog, 58 (2):206-218.
21. Love MI, Huber W, Anders S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15 (12):550.
22. Zhao M, Kong L, Liu Y, Qu H (2015). dbEMT: an epithelial-mesenchymal transition associated gene resource. Sci Rep, 5:11459.
23. Lin Y, Liu T, Cui T, et al (2020). RNAInter in 2020: RNA interactome repository with increased coverage and annotation. Nucleic Acids Res, 48 (D1):D189-D197.
24. Regel I, Mayerle J, Ujjwal Mukund M (2020). Current strategies and future perspectives for precision medicine in pancreatic cancer. Cancers (Basel), 12 (4):1024.
25. Zhang R, Liu Q, Peng J, et al (2020). CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. J Cancer, 11 (9):2371-2381.
26. Wang Z-Z, Li X-T, Li Q-J, Zhou J-X (2023). Targeting CXCL5 in Pancreatic Cancer Cells Inhibits Cancer Xenograft Growth by Reducing Proliferation and Inhibiting EMT Progression. Dig Dis Sci, 68 (3):841-851.
27. Lu C, Liu Y, Ali NM, Zhang B, Cui X (2023). The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front Immunol, 13:1039260.
28. Yao Y, Liu C, Wang B, et al (2022). HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. Cancer Lett, 533:215595.
29. Sun X, Song J, Zhang J, et al (2020). Acetylated HOXB9 at lysine 27 is of differential diagnostic value in patients with pancreatic ductal adenocarcinoma. Front Med, 14:91-100.
30. Duxbury M, Ito H, Benoit E, et al (2004). CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer, 91 (7):1384-1390.
31. Chen J, Li Q, An Y, et al (2013). CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer. Int J Oncol, 43 (3):877-885.
32. Burgos M, Cavero-Redondo I, Álvarez-Bueno C, et al (2022). Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis. Ther Adv Med Oncol, 14:17588359211072621.
33. Zheng H, Long G, Zheng Y, et al (2022). Glycolysis-related SLC2A1 is a potential pan-cancer biomarker for prognosis and immunotherapy. Cancers (Basel), 14 (21):5344.
34. Dell’Oro M, Short M, Wilson P, Bezak E (2020). Clinical limitations of photon, proton and carbon ion therapy for pancreatic cancer. Cancers (Basel), 12 (1):163.

Files	XML PDF (2MB)
Issue	Vol 53 No 7 (2024)
Section	Original Article(s)

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Askari N, Shad Pirouz M, Mafikandi V, Hadizadeh M, Mousavi SZ. The lncRNA UCA1 Enhances Pancreatic Cancer EMT by Regulating miR-708-5p and miR-135b-5p: A Bioinformatics Approach. Iran J Public Health. 2024;53(7):1659-1669.

Vancouver

Download Citation